Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634767 | 0.78 | CA1 (0.45) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6631336 | 0.78 | CA1 (0.45) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5476566 | 0.72 | — | — | |
| SCHEMBL28692073 | 0.71 | CA1 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15475186 | 0.70 | — | — | |
| SCHEMBL163610 | 0.69 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9478732 | 0.69 | AKR1C4 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29592373 | 0.67 | GPR35 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2985505 | 0.67 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL382803 | 0.67 | GPR35 (0.49) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282413-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11045456-B2 | Compositions and methods for treating COPD and other inflammatory conditions | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20180042904-A1 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| EP-3270921-A1 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | Georgia State University Research Foundation, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9468598-B2 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient | ASTRAZENECA AB (SE) | 2016-10-18 | — | — | US | disclosed |
| WO-2016154143-A1 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| CN-102764242-B | Oral dosage form comprising a PDE 4 inhibitor as active ingredient and polyvinylpyrrolidone as excipient | 塔科达有限责任公司 | 2016-09-07 | — | — | CN | disclosed |
| US-20150290180-A1 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient | ASTRAZENECA AB (SE) | 2015-10-15 | — | — | US | disclosed |
| US-20150290178-A1 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient | ASTRAZENECA AB (SE) | 2015-10-15 | — | — | US | disclosed |
| WO-1998007715-A9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998008830-A1 | THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998007715-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-26 | — | — | WO | disclosed |
| US-5712298-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-01-27 | — | — | US | disclosed |
| CN-1159804-A | Dihydrobenzofuranes | BYK GULDEN LOMBERG CHEM FAB (DE) | 1997-09-17 | — | — | CN | disclosed |
| EP-0772610-A1 | DIHYDROBENZOFURANES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1997-05-14 | — | — | EP | disclosed |
| CN-1126468-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEM FAB (DE) | 1996-07-10 | — | — | CN | disclosed |
| EP-0706513-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1996003399-A1 | DIHYDROBENZOFURANES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995001338-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045456-B2 | Compositions and methods for treating COPD and other inflammatory conditions | PDE4B, PDE4A, PDE12 | CA1 3153/4885CA2 1107/4885CA12 2368/4885 |
| US-20150290178-A1 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient | PDE12, PDE4A, PDE3A | CA1 3427/4885CA2 1505/4885CA12 3759/4885 |
| US-20180042904-A1 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | PDE4B, PDE4A, PDE12 | CA1 3153/4885CA2 1107/4885CA12 2368/4885 |
| US-20150290180-A1 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient | PDE12, PDE4A, PDE3A | CA1 3427/4885CA2 1505/4885CA12 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.